CYBB and diabetes mellitus: These findings position NOX2 as an actionable vascular target at the BII and suggest interface‐focused delivery (drug coatings, anti‐EndMT functional surfaces, responsive hydrogels) to re‐establish vessel–bone coupling and strengthen osseointegration in diabetes.